Autopsy report · NCT03945799

A Multicenter Study of Anlotinib in Hepatocellular Carcinoma (HCC) Patients at High Risk of Post Surgery Recurrence

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“The study has gotten preliminary results and stopped advanced.”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 3 years 2 months before it stopped.
28 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1, Phase 2
Sponsor: Zhejiang University
Sponsor type: University, hospital or other
Conditions: Hepatocellular Carcinoma
Interventions: Anlotinib Hydrochloride
Participants: 28
Sites: 1
Countries: China

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.